Accuracy is vital in Clinical Outcome Assessment (COA) translation. However, accuracy in COA instrument translation alone can’t guarantee consistent patient data. Two accurate COA translations may not perform in the same way. Two linguists could translate the same item, produce versions that are grammatically correct and faithful to the source, and still make different choices that influence how patients understand and answer the same question. This is one reason the linguistic validation process differs from conventional translation. The objective is to preserve the concept being measured and the way respondents are expected to interpret it.

Consider a hypothetical statement: “During the past 7 days, how often did you feel exhausted?” Depending on the target language, “exhausted” may have several plausible translations. Each translation carries slightly different associations, such as physical tiredness, lack of energy, or a broader feeling of exhaustion. None is necessarily wrong, but respondents may understand those terms differently. This could result in different answers — even when their underlying health status is the same. The same challenge appears with concepts such as:

• Pain
• Discomfort
• Difficulty
• Tiredness
• Frequency
• Severity

Beyond affecting patient data collection, these variances can impact regulatory compliance areas like recall periods and response options.

When COA Instrument Translation Uses Synonyms That Aren’t Equivalent

Clinical trial translation discussions often reach a point where two alternatives are both considered linguistically acceptable. From a measurement perspective, however, synonyms are not always interchangeable. Take an illustrative response scale moving from “a little difficult,” to “moderately difficult,” to “very difficult.” The translator should consider the relationship between each of the individual responses. If the target-language equivalent of “moderately” feels much closer to “very” than it does in the source, the progression of the scale may change. This is why context is essential. Linguists must understand what an item measures, how it relates to surrounding items, and what distinctions the developer intends respondents to make.

Concept Elaboration Helps Remove Assumptions in COA Instrument Translation

A useful concept elaboration explains what an item means in the COA instrument translation process. Sometimes it also covers what it does not mean. For example, “difficulty walking” could be used to describe the effort required to walk — not the pain experienced while walking. That distinction can change the most appropriate translation. Without that information, translators may make different, even if perfectly reasonable, assumptions.

Why Respondent Input Still Matters in COA Instrument Translation

Linguistic review in clinical trial translation services can determine whether a translation is accurate, natural, and conceptually defensible. However, it cannot always predict how the intended population will interpret it. Cognitive debriefing can address this shortcoming. It can explore what the respondent thought the question meant, what they considered when answering, and whether any terms or response options created ambiguity.  Ultimately, clinical trial sponsors and their life sciences translation partners want to achieve consistent measurement intent. Even once that intent has been successfully preserved in COA instrument translation, another challenge can arise. Teams must ensure the intent survives the transition from the approved, validated translation to the electronic environment.

Get in touch

Looking for assistance with your COA translation activities? Need guidance on COA licensing or ready to explore AI-powered COA solutions? Lionbridge has decades of COA expertise and experience assisting global pharmaceutical giants. Let’s get in touch.

References  

Wild D, Grove A, Martin M, et al. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation. Value in Health. 2005;8(2):94–104.  

FDA. Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. Final Guidance, October 2025.